News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
David Planchard: Thank you to the patients who actively participated in this research
David Planchard/aceoncology.org
Nov 12, 2023, 17:56

David Planchard: Thank you to the patients who actively participated in this research

David Planchard, Professor at the University Paris Saclay, posted on X/Twitter.

“Proud to lead this publication with P.A. Janne and all the co-authors…thank you to the patients who actively participated in this research and enabled us to offer a new therapeutic option for our EGFRmut patients in 1st-line.”

 

Image

 

Source: David Planchard/X

cancer David Planchard EGFR-mutation NSCLC OncoDaily Oncology osimertinib P.A. Janne
Special Coverage
Career
Jun 1, 2025, 15:07
Mohammad Jad Moussa: A badge of honor to wrap up my postdoc at MD Anderson
Insight
Jun 1, 2025, 14:56
Debra Patt on the Importance of Policy Engagement in Oncology at ASCO 2025
Insight
Jun 1, 2025, 14:52
Key Insights by Tom Powles from ASCO25
Insight
Jun 1, 2025, 14:50
Pashtoon Kasi Highlighted Study on Vilastobart (XTX101) + Atezolizumab in MSS Colorectal Cancer at ASCO 2025
Science
Jun 1, 2025, 14:48
First results of SURE-02 Trial presented at ASCO 2025 by Andrea Necchi
Insight
Jun 1, 2025, 14:41
Aakash Desai: Interim Results from Our Phase 1 Trial of PDL1V, a Vedotin-Based ADC Targeting PD-L1 in R/R NSCLC at ASCO 2025
Blog
Jun 1, 2025, 14:39
Christina Ip-Toma: Integrating germline and tumor genetic results to reduce disparities in cancer care
Blog
Jun 1, 2025, 14:38
Key Insights by Petros Grivas from ASCO25
Science
Jun 1, 2025, 14:38
Kriti Mittal: The ASCO special edition of the ASPIRE CoP newsletter
Oncolibrary
Jun 1, 2025, 13:48
Romiplostim for Chemotherapy-induced Thrombocytopenia Results from global phase iii trial in Gi cancers
Opinion
Jun 1, 2025, 13:42
Efficacy of IL-6R Blockade with Sarilumab in a Quadruple Immuno-Oncology Regimen for Patients with Unresectable Stage III/IV Melanoma
Oncolibrary
Jun 1, 2025, 13:02
CheckMate 214 Trial Final 9-Year Results at ASCO 2025: Nivolumab Plus Ipilimumab Continues to Show Long-Term Survival Benefit in Advanced Renal Cell Carcinoma